Overview
Dr. Mohammad Alhousani is an Assistant Professor of Medicine at the Medical University of South Carolina (MUSC) with expertise in lymphomas and related B- and T-cell disorders, including both aggressive and indolent non-Hodgkin lymphomas, Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenström macroglobulinemia, and central nervous system (CNS) lymphoma. Dr. Alhousani's clinical and research interests focus on bringing the latest advances in lymphoma care to his patients. He has a particular interest in CAR T-cell therapy, bispecific antibodies, clinical trials, and blood and marrow transplantation for patients with lymphoma. His approach emphasizes integrating innovative therapies with personalized, compassionate care tailored to each patient's needs and goals. He completed his internal medicine residency at Marshall University and his hematology and oncology fellowship at Allegheny Health Network (AHN). He then pursued an advanced fellowship in Blood and Marrow Transplantation at Mayo Clinic in Rochester, Minnesota, where he was deeply involved in the care of patients with lymphoma and CAR T-cell therapy. Dr. Alhousani is committed to advancing the field of lymphoma and cellular therapy through clinical research, multidisciplinary collaboration, and a patient-centered approach to cancer care.
His clinical expertise encompasses Chronic Myelomonocytic Leukemia (CMML) and Bone Marrow Transplant.
He is actively involved in clinical research, co-authoring 5 peer reviewed articles.
Specialties
Licenses
Hospital Affiliations
Languages Spoken
Gender
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE-MEDICAID PLAN
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MEDICARE MAPD
- INSURANCE PLAN
- MEDICARE PDP
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE SNP
- OTHER MEDICARE PART D
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- EPO
- HMO
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- EPO
- HMO
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
86 Jonathan Lucas St, 2nd Floor, 3rd Floor, Charleston, SC 29425
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
MUSC University Hospital
Robert Stuart is a Hematologist and an Oncologist practicing medicine in Charleston, South Carolina. Dr. Stuart is highly rated in 37 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Multiple Myeloma, Bone Marrow Aspiration, and Bone Marrow Transplant.
MUSC Health Hematology Oncology At Hollings Cancer Center
Dr. Thai Ho has been caring for patients affected by genitourinary cancers for over 10 years. His area of expertise and the focus of his research is in treating kidney and bladder cancers. He also sees patients with kidney, bladder, upper tract urothelial, and prostate cancers, as well as patients affected by hereditary cancer syndromes. Dr. Ho completed the Baylor College of Medicine Physician Scientist Program in 2006, internal medicine residency at Washington University in St. Louis in 2009, and Medical Oncology Fellowship at MD Anderson Cancer Center in 2012.Dr. Ho's research is funded by the National Institutes of Health and Department of Defense to better match cancer patients with targeted therapies by using precision medicine approaches to identify a cancer's unique vulnerabilities. At MUSC Hollings Cancer Center, Dr. Ho is the Director of Precision Medicine and an Associate Professor in the Division of Hematology \& Oncology. Prior to joining MUSC, Dr. Ho was an Associate Professor faculty the Mayo Clinic where he was a member of the Center for Individualized Medicine Epigenomics Group, Genomic Tumor Board, and von Hippel-Lindau Clinic. Dr. Ho is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, Nephrectomy, and Orchiectomy. Dr. Ho is currently accepting new patients.
MUSC Health Cardiology At West Ashley Medical Pavilion
Dr. Daniel Judge is a professor of medicine in cardiology at MUSC. He received his medical degree at the University of Pennsylvania, and did his post-graduate training in internal medicine, cardiology, and advanced heart failure/transplant cardiology at Johns Hopkins. He is board-certified in both cardiology and advanced heart failure/transplant cardiology.Dr. Judge takes care of adult patients with inherited forms of cardiovascular disease, as well as congestive heart failure. As director of the cardiovascular genetics program, Dr. Judge has extensive experience caring for individuals and families with inherited forms of cardiomyopathy, aortic aneurysm, amyloidosis, and cardiac involvement from other genetic conditions.He has authored more than 150 scientific manuscripts. Dr. Judge is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Cardiomyopathy, Transthyretin Amyloid Cardiomyopathy, Cardiac Amyloidosis, Heart Transplant, and Cardiac Ablation. Dr. Judge is currently accepting new patients.
Frequently Asked Questions about Dr. Mohammad M. Alhousani
How do I make an appointment with Dr. Mohammad M. Alhousani?
You can book an appointment with Dr. Mohammad M. Alhousani by calling their office at 843-792-9300. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.
Is Dr. Mohammad M. Alhousani a top-rated expert for Chronic Myelomonocytic Leukemia (CMML)?
MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mohammad M. Alhousani is classified as an Experienced expert for Chronic Myelomonocytic Leukemia (CMML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
What conditions does Dr. Mohammad M. Alhousani specialize in?
While Dr. Mohammad M. Alhousani is a Hematology Oncology, they have specific expertise in Chronic Myelomonocytic Leukemia (CMML), Bone Marrow Transplant. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.
Does Dr. Mohammad M. Alhousani participate in research or clinical trials?
Yes. Dr. Mohammad M. Alhousani has published 5 articles and abstracts on conditions like Chronic Myelomonocytic Leukemia (CMML). You can view a list of Dr. Mohammad M. Alhousani's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Does Dr. Mohammad M. Alhousani accept my insurance?
Dr. Mohammad M. Alhousani accepts most major insurance plans, including Absolute Total Care South Carolina and Anthem BCBS. We recommend calling the office directly at 843-792-9300 to verify that your specific plan is currently accepted before your visit.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Bone Marrow TransplantDr. Alhousani isExperienced. Learn about Bone Marrow Transplant.
- Chronic Myelomonocytic Leukemia (CMML)Dr. Alhousani isExperienced. Learn about Chronic Myelomonocytic Leukemia (CMML).